Abiopharma

🔍 Reprogrammed Interchange LLC (Executive)

Company: Vor Biopharma Inc. (VOR)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Sold 554,612 shares of Common Stock at $1.9961 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 36,329,955.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 453,016 shares of Common Stock at $1.9285 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 35,876,939.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 400,000 shares of Common Stock at $1.9682 per share (Direct)
  Date: 2025-09-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 35,476,939.00 | transaction_form_type: 4 | Footnotes: F4, F2

Footnotes:

• F1: This transaction was executed in multiple trades at prices ranging from $1.99 to $2.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F2: The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
• F3: This transaction was executed in multiple trades at prices ranging from $1.91 to $2.005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F4: This transaction was executed in multiple trades at prices ranging from $1.935 to $1.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.